Popular terms

[SEARCH]

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      
           
This page is updated frequently with new Expression Vector-related patent applications. Subscribe to the Expression Vector RSS feed to automatically get the update: related Expression RSS feeds. RSS updates for this page: Expression Vector RSS RSS



Date/App# patent app List of recent Expression Vector-related patents
08/20/15
20150232867 
 Heavy metal reduction in planta patent thumbnailHeavy metal reduction in planta
There is described a mutant, non-naturally occurring or transgenic plant or plant cell comprising (a) a polynucleotide selected from the group consisting of: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 71% sequence identity to seq id nos: 1, 2, 27, 28 or 29 or 51; or (ii) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos: 3 to 23 or 30 to 50; or (iii) a polynucleotide encoding a ntmrp polypeptide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos. 24 to 26 or 52, and wherein the polypeptide has heavy metal transporter activity; or (b) a polynucleotide construct of at least 15 contiguous nucleotides in length that is at least 65% identical to a region of any of seq id nos: 1 to 23 or 27 to 51; or (c) a double-stranded rna comprising at least two sequences that are at least partially complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence and wherein at least one of the sequences comprises at least 10 contiguous nucleotides of ntmrp rna; or (d) an expression vector comprising the polynucleotide as set forth in (i), (ii) or (iii) or the polynucleotide construct as set forth in (b)..
Philip Morris Products S.a.


08/20/15
20150232822 
 Dna polymerases having improved labeled nucleotide incorporation properties patent thumbnailDna polymerases having improved labeled nucleotide incorporation properties
In addition to providing novel mutant dna polymerases, the invention also provides polynucleotides encoding the subject mutant dna polymerases. The polynucleotides provided may comprise expression vectors for the recombinant production of the mutant polymerases.

08/20/15
20150232522 
 Brown adipocyte differentiation-inducing agent patent thumbnailBrown adipocyte differentiation-inducing agent
The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) creg1 protein or (2) an expression vector carrying creg1 gene..
Chubu University Educational Foundation


08/20/15
20150231208 
 Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain patent thumbnailTreatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
The present invention relates to use of cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia.
Nsgene A/s


08/20/15
20150231168 
 Methods for sustained and regulatable gene expression using viral based expression vectors patent thumbnailMethods for sustained and regulatable gene expression using viral based expression vectors
Disclosed are genetic expression cassettes, and vectors comprising them useful for the delivery of isolated nucleic acid segments including those expressing or encoding one or more selected therapeutic constructs (including, without limitation, therapeutic peptides, polypeptides, ribozymes, or catalytic rna molecules), to one or more selected cells or tissues of a vertebrate animal. Methods employing the disclosed genetic constructs in the development of gene therapy-based viral vector systems are also disclosed.
University Of Florida Research Foundation, Inc.


08/13/15
20150225740 
 Importation of mitochodrial protein by an enhanced allotopic approach patent thumbnailImportation of mitochodrial protein by an enhanced allotopic approach
An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)


08/13/15
20150225739 
 Expression vectors comprising ires element and the multiple expression gene system thereof patent thumbnailExpression vectors comprising ires element and the multiple expression gene system thereof
The present invention provides an expression vector comprising an internal ribosome entry site (ires) element, comprising a sequence of seq id no: 1, wherein the sequence is an ires element from a gene icp35 of white spot syndrome virus. The expression vector can be easily operated in insect cells or crustacean cells and has excellent expression efficiency due to having such an ires element.
National Taiwan University


08/06/15
20150218610 
 Protein production method patent thumbnailProtein production method
This invention relates to a method for producing a protein of interest, comprising introducing a protein expression vector which comprises a gene fragment a gene fragment comprising a dna encoding a protein of interest and a selectable marker gene and transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell to obtain a mammalian cell capable of expressing the protein of interest; and suspension-culturing the mammalian cell; and a suspension mammalian cell capable of expressing the protein of interest.. .
Inter-university Research-institute Corporation Research Organization Of Information & Systems


08/06/15
20150218588 
 Cytochrome p450 and use thereof for the enzymatic oxidation of terpenes patent thumbnailCytochrome p450 and use thereof for the enzymatic oxidation of terpenes
The present invention provides the nucleic acid and the amino acid sequences of a cytochrome p450 capable of oxidizing terpene molecules. It also provides a method of oxidizing terpene molecules comprising contacting the cytochrome p450 of the invention with the terpene molecule intended to be oxidized.
Firmenich Sa


08/06/15
20150218584 
 Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences patent thumbnailExpression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5′ of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus. In particular embodiments, the chimeric promoter regulatory sequence comprises sequence elements derived from the murine or the human cytomegalovirus ie1 promoter and from the human and/or the simian cytomegalovirus ie1 region.
Lonza Biologics Plc.


08/06/15
20150218582 

Fungal resistant plants expressing rlk1


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an rlk1 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


08/06/15
20150218555 

Synthetic promoter for modulating gene expression


The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed using selected pdx-1 activation sites such as those observed in the human insulin promoter (hip). In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide..
Baylor College Of Medicine


08/06/15
20150218552 

Rnai based selection system


The present invention provides a novel rnai based selection system for selecting host cells that have incorporated an expression vector.. .
Qiagen Gmbh


08/06/15
20150218239 

Fcrn antagonists and methods of use


Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System


08/06/15
20150216999 

Compositions and methods for treating cardiovascular diseases using smad3


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microrna, sirna or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that any disease specific promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body.
Kiromic, Llc


08/06/15
20150216966 

Cellular vaccine and inducing an immune response in a subject


The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd


08/06/15
20150216948 

Cytochrome p450 suicide gene system


The invention relates to a modified human cyp4b1 protein and a nucleic acid encoding for the modified human cyp4b1 protein. The invention further relates to an expression vector comprising a nucleic acid encoding for a modified human cyp4b1 protein, as well as to a cell comprising a modified cyp4b1 protein.

07/30/15
20150211018 

Fungal resistant plants expressing rlk2


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an rlk2 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


07/30/15
20150211013 

Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi


The invention is generally directed to modified filamentous fungal host cells comprising one or more nucleic acids encoding one or more polypeptides under the control of one or more promoters that are functional in said cells. Methods of using the modified cells to express one or more polypeptides are also disclosed, including methods of screening cells transformed with one or more expression vectors comprising nucleic acids derived from synthetic or genomic nucleic acids including, cdnas.
Dyadic International, Inc.


07/30/15
20150211012 

Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine


The invention relates to polynucleotides and recombinant cell strains comprising the polynucleotides and the uses thereof for the delivery of the polypeptides encoded by the polynucleotides to a subject in need thereof. In particular, the invention refers to polynucleotides comprising a polypeptide of interest, auxotrophy-complementing genes and the use thereof in a mycobacterial double auxotrophic host cell to achieve the stable expression of the polypeptide of interest by using an antibiotic-free plasmid selection system..
FundaciÓ Privada Institut De Recerca De La Sida - Caixa


07/23/15
20150203826 

Novel enzymes, enzyme components and uses thereof


The invention provides nucleic acid molecules which encodes a novel fatty acid desaturase, kcs, kcr and/or lacs from thraustochytrium aureum and sphaeroforma arctica. The invention also provides recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (lcpufas), e.g., ara, epa and dha and for screening for delta-4 desaturases..
Basf (china) Company Limited


07/23/15
20150203590 

Lipoprotein-associated phospholipase a2 antibody compositions and methods of use


The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.

07/23/15
20150203546 

Scytodes venom fiber peptides, nucleic acids and methods of making and using


The present invention is directed to spider silk-like fibers, peptides comprising the fibers, nucleic acids encoding the peptides, nucleic acid constructs and recombinant expression vectors, fusion peptides and methods of making and using the foregoing.. .

07/23/15
20150203544 

Immune system mediator


The present invention discloses an isolated nucleic acid molecule encoding an israa polypeptide comprising a nucleotide sequence exhibiting at least 70% homology to the sequence represented by the nucleotide sequence seq id no: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule..
Arabian Gulf University


07/23/15
20150202271 

Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope


The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of vegf and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
Anges Mg, Inc.


07/16/15
20150197772 

Mammalian expression vector puhab


The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (mcs), designated puhab. The puhab vector comprises a high copy replication origin (cole1), a drug resistance gene (tk-hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hcmv/intron).
Merck Sharp & Dohme Corp.


07/16/15
20150197738 

Acid stable prolyl endopeptidases for degrading gluten


Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance. The present invention provides recombinant expression vectors encoding the proteases of the invention and methods for using such vectors to produce the encoded proteases.
Alvine Pharmaceuticals, Inc.


07/16/15
20150196621 

Compositions for the prevention and treatment of neuroinjury and methods of use thereof


A method for preventing or ameliorating secondary neuronal injury and inflammation following traumatic brain injury (tbi) is disclosed. The method comprises the step of administering into a subject in need of such treatment an effective amount of a pharmaceutical composition containing a neuregulin (nrg), a variant of nrg, or an expression vector encoding a nrg or a variant of nrg..
Brain-gen Biotech


07/16/15
20150196487 

Vaccine formulations comprising saponin-containing adjuvants


The present invention provides for a novel oil-in-water (o/w) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof..
Merial Limited


07/09/15
20150191703 

Production of infectious influenza viruses


The invention relates to a method for producing influenza infectious viruses wherein cho cells are infected with a seed of infectious influenza virus which has been generated by transfecting cells with an appropriate set of expression vectors. The invention also relates to a recombination cassette, and to a vector comprising said recombination cassette, that may be used in methods for producing infectious viruses, and particularly in the method according to the invention..
Sanofi Pasteur


07/02/15
20150184216 

Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and producing aglycones using the microorganism, the oxidoreductase and the gene


The present invention relates to the novel rhizobium sp. Gin611 kctc11708bp or to cell extracts thereof, to a novel oxidoreductase which exhibits a glycolytic activity, to a gene encoding the oxidoreductase, to a recombinant strain comprising recombinant vector proteins or to an expression vector encoding recombinant proteins, and to a method for the glycolysis of natural products using same as a biocatalyst.
Amorepacific Corporation


07/02/15
20150184215 

Development of the soluble recombinant crm197 production by e. coli


A method for recombinant production of a crm197 protein includes culturing a recombinant escherichia coli cell to produce said crm197 protein, and isolating said crm197 protein. The recombinant escherichia coli cell includes an expression vector, which contains a nucleic acid molecule that encodes a fusion protein that includes an e.
Development Center For Biotechnology


07/02/15
20150184191 

Yield and stress tolerance in transgenic plants iv


Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention have been shown to confer at least one regulatory activity and confer increased yield, greater height, greater early season growth, greater canopy coverage, greater stem diameter, greater late season vigor, increased secondary rooting, more rapid germination, greater cold tolerance, greater tolerance to water deprivation, reduced stomatal conductance, altered c/n sensing, increased low nitrogen tolerance, increased low phosphorus tolerance, or increased tolerance to hyperosmotic stress as compared to the control plant as compared to a control plant..
Monsanto Technology Llc


07/02/15
20150184188 

Plants with enhanced size and growth rate


Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention regulate transcription in these plants and have been shown to confer at least one regulatory activity that results in increased size, biomass, growth rate, and/or yield as compared to a control plant..
Mendel Biotechnology, Inc.


07/02/15
20150183856 

Novel monoclonal antibody binding specifically to dll4 and use thereof


The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (dll4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.. .
Hanwha Chemical Corporattion


07/02/15
20150182617 

Glycoproteins for pseudotyping lentivectors


The invention relates to compositions and methods based on the use of viral g proteins to pseudotype vectors. The viral g proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors.
Theravectys


07/02/15
20150182581 

Peptide inhibitors as novel anti-hiv therapeutics


The present invention relates to synthetic peptide inhibitors (seq id no. 67-71) useful as anti-hiv therapeutics.
Council Of Scientific & Industrial Research


06/25/15
20150176029 

Method for producing beta-santalene


The present invention provides a method of producing β-santalene, said method comprising contacting at least one polypeptide with farnesyl pyrophosphate (fpp). In particular, said method may be carried out in vitro or in vivo to produce β-santalene, a very useful compound in the fields of perfumery and flavoring.
Firmenich Sa


06/25/15
20150176020 

Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases


The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galactosyltransferases and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation.
Stichting Dienst Landbouwkundig Onderzoek


06/25/15
20150175713 

Lh-type bispecific antibody


Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (lh-diabody type bispecific antibody) characterized in that an l-chain is located in the n-terminal side in each polypeptide (lh type); a humanized high-functional bispecific antibody which contains said lh diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule..
Tohoku University


06/25/15
20150175701 

Ovr110 antibody compositions and methods of use


Isolated antibodies and antigen binding fragments thereof directed against ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an ovr110-expressing cancer cells and alleviating or treating an ovr110-expressing cancer in a mammal.
Diadexus, Inc.


06/18/15
20150166662 

Glycan-modified anti-cd4 antibodies for hiv prevention and therapy


Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..

06/18/15
20150166638 

Anti-hsv antibody


The invention relates to an anti-hsv antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of hsv-associated diseases in a subject; as defined in the claims.. .
Rheinische Friedrich-wilhelms-universität Bonn


06/18/15
20150166635 

Gpr88 mini-promoters


Isolated polynucleotides comprising a gpr88 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia


06/18/15
20150165025 

Methods for treating cancer using anti-pd-1 antibodies


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.


06/11/15
20150158921 

Alphao-superfamily conotoxin peptide, pharmaceutical composition and use thereof


The present invention pertains to fields of biochemistry and molecular biology, relates to an αo-superfamily conotoxin peptide, pharmaceutical composition thereof, preparation method and use thereof. The present invention further relates to a propeptide of the conotoxin peptide, nucleic acid construct thereof, expression vector and transformed cell thereof, and fusion protein thereof.
Hainan University


06/04/15
20150152406 

Transposition-mediated identification of specific binding or functional proteins


The method disclosed herein describes a novel technology offering unparalleled efficiency, flexibility, utility and speed for the discovery and optimization of polypeptides having desired binding specificity and/or functionality, including antigen-binding molecules such as antibodies and fragments thereof, for desired functional and/or binding phenotypes. The novel method is based on transposable constructs and diverse dna libraries cloned into transposable vectors and their transfection into host cells by concomitant transient expression of a functional transposase enzyme.
Nbe-therapeutics Llc


05/28/15
20150147805 

Vectors, host cells, and methods of production and uses


Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody dna and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding dna into the vectors.
Janssen Biotech, Inc.


05/28/15
20150147794 

Ethane-1,2-diol producing microorganism and a producing ethane-1,2-diol from d-xylose using the same


Disclosed herein is a microorganism capable of producing ethane-1,2-diol from d-xylose, and a method for producing ethane-1,2-diol using the same. More specifically, the present invention relates to an engineered escherichia coli (e.
Myongji University Industry And Academia Cooperation Foundation


05/21/15
20150143585 

Biomass production increasing gene and transgenic plant using same


The present disclosure relates to, inter alia, a gene for increasing biomass production isolated from arabidopsis thaliana, and a method for producing a transgenic plant by using the same. More specifically, the present disclosure provides, inter alia, a composition for increasing production of plant biomass, a recombinant expression vector and a transgenic plant, comprising a base sequence encoding for the amino acid sequence of sequence number 2.
Postech Academy-industry Foundation


05/21/15
20150143556 

Mutant alpha-synuclein, and methods using same


The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (a56), at the alanine at position 76 (a76), at the methionine at position 127 (m127) and/or at the valine at position 118 (v118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.


05/21/15
20150141347 

Murine anti-ny-eso-1 t cell receptors


The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serv.


05/21/15
20150140607 

Cho expression system


The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a cho cell line.
Sanofi


05/21/15
20150140591 

Cell engineering using rnas


The invention concerns the field of cell culture technology. It concerns rna having a specific sequence, expression vectors encoding said rna, production host cell lines comprising said rna, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said rnas, such as small non-coding rnas, preferably micrornas (mirnas).
Boehringer Ingelheim International Gmbh


05/14/15
20150135360 

Stress tolerance in plants


Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress).

05/14/15
20150133379 

Cosmetic composition for improving skin conditions comprising fusion protein


The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein.

05/14/15
20150132823 

Alpha-amylase variants


The invention relates to a variant of a parent termamyl-like alpha-amylase, comprising mutations in two, three, four, five or six regions/positions. The variants have increased stability at high temperatures (relative to the parent).

05/14/15
20150132770 

Pregnancy-associated plasma protein-a2 (papp-a2) polynucleotides


The present invention provides pregnancy associated plasma protein a2 (papp-a2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode papp-a2, expression vectors for the production of purified papp-a2, antibodies capable of binding specifically to papp-a2, hybridization probes or oligonucleotides for the detection of papp-a2-encoding nucleotide sequences, genetically engineered host cells for the expression of papp-a2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of papp-a2, are also described..

05/07/15
20150126456 

Method and pharmaceutical composition for use in the treatment of cancer


The present invention relates to a soluble peptide comprising the amino acids sequence: krfyvvmwkk (seq id no: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier..
Assistance Publique-hopitaux De Paris


05/07/15
20150126452 

Protein assembler


The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc.
Albert-luding-universitÄt Freiburg


05/07/15
20150125951 

Mutant alpha-synuclein, and methods using same


The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (a56), at the alanine at position 76 (a76), at the methionine at position 127 (m127) and/or at the valine at position 118 (v118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.


04/30/15
20150119332 

Isoform-selective inhibitors and activators of pde3 cyclic nucleotide phosphodiesterases


The present invention concerns methods and compositions related to type 3 phosphodiesterases (pde3). Certain embodiments concern isolated peptides corresponding to various pde3a isoforms and/or site-specific mutants of pde3a isoforms, along with expression vectors encoding such isoforms or mutants.
The United States Government, As Represented By The Department Of Veterans Affairs


04/30/15
20150118754 

Stable expression system for eukaryotic cells


The present invention related to a polynucleotide sequence and an expression vector comprising at least one gene encoding a stress resistance protein, at least one gene encoding a selection marker, at least one gene encoding an expression protein, at least one matrix attachment region and a transcription terminator, all of which are operably connected to each other. The present invention further relates to a host cell comprising the expression vector.
Biogenomics Limited


04/30/15
20150118744 

Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector


An oligonucleotide that inhibits the binding of a serine/arginine-rich protein 30c (srp30c) to a pre-mrna of a glucocorticoid receptor gene in vivo.. .
National University Corporation Tokyo University Of Agriculture And Technology


04/23/15
20150110744 

Peptide agents for cancer therapy


There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence rxkxkxxxxr wherein k and r are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence rskaknplyr (seq id. No.
Inter-k Pty Limited


04/16/15
20150106971 

Threonine synthase from nicotiana tabacum and methods and uses thereof


There is disclosed a mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a threonine synthase and having at least 90% sequence identity to seq id no:1, seq id no:2 or seq id no:3 or at least 87% sequence identity to seq id no:4, or seq id no:5; (ii) a polypeptide encoded by any one of said polynucleotides set forth in (i); or (iii) a polypeptide having at least 95% sequence identity to seq id no:6, seq id no:7 or seq id no:8; or (iv) a construct, vector or expression vector comprising the polynucleotide as set forth in (i).. .
Philip Morris Products S.a.


04/16/15
20150104870 

Neuronal differentiation promoter


The present invention provides an agent for promoting neuronal differentiation of neural stem cells, which contains a p38 inhibitor. In addition, the present invention provides a method of promoting neuronal differentiation of neural stem cells, which includes cultivating neural stem cells in the presence of a p38 inhibitor.
Keio University


04/16/15
20150104866 

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.


04/16/15
20150104832 

Method for modulating gene expression by modifying the cpg content


The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of cpg dinucleotides. The invention also relates to modified nucleic acids and expression vectors..
Geneart Ag


04/16/15
20150104433 

Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains


The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (ltr) of proviral dna of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.


04/09/15
20150099707 

Modified pseudomonas exotoxin a


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
Hoffmann-la Roche Inc.


04/09/15
20150098925 

Compositions and methods for treating cardiovascular diseases using disease-specific promoter


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microrna, sirna or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body.
Kiromic, Llc


04/02/15
20150093392 

Antibodies


The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to cdh17 with high affinity. Nucleic acid molecules encoding cdh17 antibodies, expression vectors, host cells and methods for expressing cdh17 antibodies are also provided.
Oxford Bio Therapeutics Ltd


03/26/15
20150087054 

Importation of mitochodrial protein by an enhanced allotopic approach


An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)


03/26/15
20150087053 

Compositions and methods for increasing the expression and signalling of proteins on cell surfaces


The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces.
The Johns Hopkins University


03/26/15
20150087047 

Process for production of recombinant proteins as a soluble form


A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein.
Jnc Corporation


03/26/15
20150086588 

Parainfluenza virus 5 based vaccines


The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (piv5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (hn) gene and the large rna polymerase protein (l) gene of the piv5 genome.
University Of Georgia Research Foundation, Inc.


03/19/15
20150079070 

Hyperglycosylated binding polypeptides


Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a ch1 domain (e.g., a human igg1 ch1 domain), wherein the ch1 domain has an engineered n-linked glycosylation site at amino acid position 114, according to kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


03/12/15
20150072898 

Broad host range expression vector for diverse prokaryotes


The invention relates to a synthetic nucleic acid molecule for expressing at least one nucleotide sequence of interest in at least one prokaryotic host cell, comprising, amongst others, at least one replication module comprising at least one replication cassette for promoting replication of the nucleic acid molecule in gram-negative organisms and at least one replication cassette for promoting replication of the nucleic acid molecule in gram-positive organisms, and at least one expression module for promoting expression of the nucleotide sequence of interest in the host cell, wherein each module is flanked at both ends by at least one unique restriction site. The invention further concerns a method for producing a shuttle vector comprising several modules, wherein said shuttle vector is designed by selecting each of said modules such that the vector is optimized for its intended use..
Westfaelische Wilhelms-universitaet Muenster


03/12/15
20150072417 

Method of nuclear reprogramming


A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an oct family gene, a klf family gene, a sox family gene, a myc family gene, a lin family gene, and nanog gene.
Kyoto University


03/12/15
20150072368 

Transcription units and the use thereof in expression vectors


Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium..
Laboratoire Francais Du Fractionnement Et Des Biotechnologies


03/05/15
20150065376 

Expression constructs encoding g protein coupled receptors and methods of use thereof


Expression vectors comprising a first nucleic acid sequence encoding a g protein coupled receptor (gpcr), wherein the gpcr encoded thereby is expressed as a fusion protein with a first detectable marker/signal, and a second nucleic acid sequence encoding a second polypeptide that is or comprises a second detectable marker/signal, wherein the second polypeptide is expressed as a fusion protein with a membrane localizing sequence are encompassed herein. The first nucleic acid sequence encoding the gpcr and the second nucleic acid sequence encoding the second polypeptide are under the transcriptional control of the same promoter and are operably linked via, for example, an internal ribosomal entry site (ires).

03/05/15
20150064209 

Methods for generating immunity to antigen


Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen.
Microvax, Llc


02/26/15
20150059015 

Fungal resistant plants expressing acd


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an acd protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


02/26/15
20150056210 

Anti-adamts-5 antibody, derivatives and uses thereof


The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the spacer domain of adamts-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.. .
Rottapharm Biotech S.r.l.


02/26/15
20150056168 

Bacterial expression system


The present invention provides a bacterial expression system for expressing a nucleic acid comprising: (a) dna encoding a group 5 rna polymerase sigma factor; and (b) an expression cassette comprising a promoter recognised by the group 5 rna polymerase sigma factor operably linked to a heterologous nucleic acid; wherein (a) and (b) are located on the same expression vector, separate expression vectors or are integrated into the bacterial host genome.. .
The University Of Nottingham


02/19/15
20150052629 

Fungal resistant plants expressing ocp3


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an ocp3 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


02/19/15
20150051267 

Bicistronic gene transfer tools for delivery of mirnas and protein coding sequences


Compositions and methods relating to microrna (mirna) technology are disclosed. In particular, microrna (mirna) expression vectors and methods for the treatment of sensory disorders, e.g., for the treatment of hearing loss, are described..
Purdue Research Foundation


02/19/15
20150050270 

Antibodies to bradykinin b1 receptor ligands


The invention provides antibodies that specifically bind to kallidin or des-arg10-kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-kallidin or des-arg10-kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof.
Sanofi




Popular terms: [SEARCH]

Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.474

5352

2 - 1 - 101